3rd Annual Advances in Immuno-Oncology Congress

Hits:1100 Date: 4/12/2018

Oxford Global is pleased to share with you the final agenda for our highly anticipated

3rd Annual Advances in Immuno-Oncology Congress, taking place on 24 - 25 May 2018

in London, UK.

Across two days, the congress will bring together over 300 delegates to discuss the latest case

studies and novel strategies currently being used to develop cancer immunotherapies.

Alongside presentations on companion diagnostics, preclinical models and clinical trial design,

there is a dedicated brand new stream on genomics, precision medicine and the microbiome for

cancer immunotherapy.

Unmissable presentations include:

♦ Translational Biomarkers in Immune Checkpoint and Adoptive T Cell Therapy - Sara

Brett, Director Translational Immunology, GlaxoSmithKline

♦ Off-The-Shelf Immunotherapy - Troels Jordansen, Chief Executive Officer, Glycostem

Therapeutics

♦ Preclinical Development of BiTE Technology - Roman Kischel, Director Research - BiTE

Technology, Amgen

♦ Takin a Preclinical Model Into Clinical Trials - Paul Sondel, Professor of Pediatrics,

HUman Oncology and Genetics, Univeristy of Wisconsin

VIEW THE AGENDA HERE>>

KEY REASONS TO ATTEND?

♦ Gain an in-depth industry perspective from leading experts on emerging trends

in molecular oncology and cell based therapeutics

♦ Benefit from dedicated networking opportunities to engage in scientific discussion

with senior directors and decision makers from major biotechnology and pharmaceutical

companies

♦ Learn more about precision medicine for cancer immunotherapy

♦ Hear over 50 presentations that provide a comprehensive look at immuno-oncology

drug development from early therapeutic strategies to clinical trial data

♦ Experience a more interactive program than ever with panel & roundtable

discussions and workshops to ensure high-level debate on the key opportunities and

challenges in this field

For further information on how to save on your attendance and what discounts we have